Qiagen (NYSE:QGEN) (NYSE: QGEN) is a global leader in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Founded in 1984 and headquartered in Hilden, Germany, the company develops and supplies products that enable the extraction, purification, amplification and detection of DNA and RNA from complex biological samples. Qiagen’s solutions underpin a wide range of applications, including infectious disease testing, cancer diagnostics, genetic research and blood screening.
The company’s portfolio encompasses a variety of consumables, instruments and software. Sample preparation tools such as spin columns, automation platforms and flexible kits ensure reliable nucleic acid recovery. Qiagen’s amplification technologies include real-time PCR instruments, digital PCR systems and multiplex assays, supporting high-sensitivity detection of pathogens and genomic targets. In addition, the firm offers comprehensive bioinformatics tools that streamline data analysis, interpretation and workflow integration for both clinical and research laboratories.
Qiagen serves customers in over 35 countries, with major operations in Europe, North America, the Asia-Pacific region and Latin America. Its end markets include clinical laboratories, molecular diagnostics companies, pharmaceutical and biotechnology firms, academic institutions and government agencies. The company maintains a broad distribution network and collaborates with healthcare providers and research organizations to advance molecular testing capabilities and address emerging public health challenges.
Led by Chief Executive Officer Thierry Bernard, Qiagen places a strong emphasis on innovation, quality and customer support. The executive team focuses on expanding the company’s assay portfolio through strategic partnerships, acquisitions and internally driven research and development. By investing in new diagnostic platforms and digital solutions, Qiagen aims to enhance the speed, accuracy and accessibility of molecular testing, supporting both routine healthcare delivery and cutting-edge life science research.
